• LAST PRICE
    0.6710
  • TODAY'S CHANGE (%)
    Trending Down-0.0141 (-2.0581%)
  • Bid / Lots
    0.6720/ 10
  • Ask / Lots
    0.6883/ 13
  • Open / Previous Close
    0.6900 / 0.6851
  • Day Range
    Low 0.6552
    High 0.6900
  • 52 Week Range
    Low 0.5528
    High 2.5300
  • Volume
    45,124
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.6851
TimeVolumeBLRX
09:32 ET9370.6847
09:34 ET4400.6626
09:38 ET38400.6552
09:45 ET20000.6601
09:50 ET7000.6602
09:54 ET3000.6603
10:14 ET7500.6602
10:17 ET4070.6635
10:21 ET12000.6603
10:24 ET23150.6724
10:35 ET19930.6605
10:37 ET12000.6724
10:51 ET10000.6683
10:53 ET29560.689
11:00 ET4000.6771
11:08 ET89250.6696
11:11 ET101000.6697
11:18 ET15000.6887
11:22 ET1000.6704
11:27 ET5000.679099
11:29 ET9000.671
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesBLRX
BioLine RX Ltd
52.7M
-0.7x
---
United StatesPTN
Palatin Technologies Inc
37.9M
-0.9x
---
United StatesCIPI
Correlate Energy Corp
50.6M
-3.5x
---
United StatesHCWB
HCW Biologics Inc
45.4M
-1.7x
---
United StatesKRON
Kronos Bio Inc
63.1M
-0.5x
---
United StatesKZR
Kezar Life Sciences Inc
59.5M
-0.6x
---
As of 2024-05-10

Company Information

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Contact Information

Headquarters
Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
Phone
---
Fax
---

Executives

Chairman of the Board
Aharon Schwartz
Chief Executive Officer
Philip Serlin
Chief Financial Officer
Mali Zeevi
Vice President - Development
Ella Sorani
Vice President-Clinical & Medical Affairs
Abi Vainstein-Haras

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$52.7M
Revenue (TTM)
$4.8M
Shares Outstanding
79.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.52
EPS
$-0.95
Book Value
$0.18
P/E Ratio
-0.7x
Price/Sales (TTM)
11.0
Price/Cash Flow (TTM)
---
Operating Margin
-1,035.29%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.